196 related articles for article (PubMed ID: 25924666)
21. Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects.
Antonio L; Caerels S; Jardi F; Delaunay E; Vanderschueren D
Andrology; 2019 May; 7(3):302-306. PubMed ID: 30851011
[TBL] [Abstract][Full Text] [Related]
22. Waist circumference provides an indication of numerous cardiometabolic risk factors in adults with cerebral palsy.
Ryan JM; Crowley VE; Hensey O; McGahey A; Gormley J
Arch Phys Med Rehabil; 2014 Aug; 95(8):1540-6. PubMed ID: 24742941
[TBL] [Abstract][Full Text] [Related]
23. Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study).
Shigehara K; Konaka H; Nohara T; Izumi K; Kitagawa Y; Kadono Y; Iwamoto T; Koh E; Mizokami A; Namiki M
Andrologia; 2018 Feb; 50(1):. PubMed ID: 28497534
[TBL] [Abstract][Full Text] [Related]
24. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study.
Yassin AA; Nettleship J; Almehmadi Y; Salman M; Saad F
Andrologia; 2016 Sep; 48(7):793-9. PubMed ID: 26762680
[TBL] [Abstract][Full Text] [Related]
25. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
[TBL] [Abstract][Full Text] [Related]
26. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
[TBL] [Abstract][Full Text] [Related]
27. The effect of physiotherapy in addition to testosterone replacement therapy on the efficiency of the motor system in men with hypogonadism.
Bacevičienė R; Valonytė L; Ceponis J
Medicina (Kaunas); 2013; 49(2):71-7. PubMed ID: 23888342
[TBL] [Abstract][Full Text] [Related]
28. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
[TBL] [Abstract][Full Text] [Related]
29. Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters.
Dias JP; Shardell MD; Carlson OD; Melvin D; Caturegli G; Ferrucci L; Chia CW; Egan JM; Basaria S
Andrology; 2017 Jan; 5(1):31-40. PubMed ID: 27792869
[TBL] [Abstract][Full Text] [Related]
30. Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/Kallmann syndrome and effects of different modalities of hormonal treatment: a single-center study of 281 patients.
Trabado S; Maione L; Bry-Gauillard H; Affres H; Salenave S; Sarfati J; Bouvattier C; Delemer B; Chanson P; Le Bouc Y; Brailly-Tabard S; Young J
J Clin Endocrinol Metab; 2014 Feb; 99(2):E268-75. PubMed ID: 24243640
[TBL] [Abstract][Full Text] [Related]
31. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
32. Comparison of insulin resistance and serum high-sensitivity C-reactive protein levels according to the fasting blood glucose subgroups divided by the newly recommended criteria for fasting hyperglycemia in 10059 healthy Koreans.
Rhee EJ; Kim YC; Lee WY; Jung CH; Sung KC; Ryu SH; Oh KW; Kim SW
Metabolism; 2006 Feb; 55(2):183-7. PubMed ID: 16423624
[TBL] [Abstract][Full Text] [Related]
33. Changes in levels of testosterone, insulin sensitivity and metabolic profiles during GnRH therapy: Reciprocity between insulin sensitivity and pituitary responsiveness to GnRH in teenage and young male patients with congenital hypogonadotropic hypogonadism.
Fan HQ; Wang YC; He W; Zhou HW; Yang T
Clin Endocrinol (Oxf); 2022 Dec; 97(6):783-791. PubMed ID: 36181235
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia.
Krysiak R; Gilowski W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):270-4. PubMed ID: 26031507
[TBL] [Abstract][Full Text] [Related]
35. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
36. CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity.
Fernández-Real JM; Broch M; Richart C; Vendrell J; López-Bermejo A; Ricart W
J Clin Endocrinol Metab; 2003 Apr; 88(4):1780-4. PubMed ID: 12679473
[TBL] [Abstract][Full Text] [Related]
37. The association of low-grade inflammation, urinary albumin, and insulin resistance with metabolic syndrome in nondiabetic Taiwanese.
Lee IT; Lee WJ; Huang CN; H-H Sheu W
Metabolism; 2007 Dec; 56(12):1708-13. PubMed ID: 17998025
[TBL] [Abstract][Full Text] [Related]
38. Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions.
Aydogan U; Aydogdu A; Akbulut H; Sonmez A; Yuksel S; Basaran Y; Uzun O; Bolu E; Saglam K
Endocr J; 2012; 59(12):1099-105. PubMed ID: 22972022
[TBL] [Abstract][Full Text] [Related]
39. Erectile dysfunction, obesity, insulin resistance, and their relationship with testosterone levels in eugonadal patients in an andrology clinic setting.
Knoblovits P; Costanzo PR; Valzacchi GJ; Gueglio G; Layus AO; Kozak AE; Balzaretti MI; Litwak LE
J Androl; 2010; 31(3):263-70. PubMed ID: 19834133
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
